Clinical Trial

A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases

Terminated Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
pipeline adjustment
Summary
This is a prospective, single-arm, open-label and dose-escalation Investigator Initialed study to evaluate LUCAR-G79 in adult subjects with relapsed/refractory autoimmune diseases.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-06-30; most recent amendment 2026-06-14.
Status change: Recruiting → Terminated 2026-06-14
Status change: Not Yet Recruiting → Recruiting 2025-07-17
Trial Details
NCT Number NCT07049081
Lead Sponsor Nanjing Legend Biotech Co.
Conditions Relapsed/Refractory Autoimmune Diseases
Enrollment 3 participants
Start Date 2025-07-17
Primary Completion 2026-03-20 (estimated)
Study Completion 2026-03-20 (estimated)
Updated on ClinicalTrials.gov 2026-06-16